Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi ‐database, non‐interventional post‐authorization safety study

Abstract This non‐interventional, multi‐database, analytical cohort study assessed the cardiovascular (CV) safety of vildagliptin vs. other non‐insulin antidiabetic drugs (NIADs) using real‐world data from five European electronic healthcare databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (95% CIs) for the outcomes of interest (myocardial infarction [MI], acute coronary syndrome [ACS], stroke, congestive heart failure [CHF], individually and as a composite) were estimated using negative binomial regression. Approximately 2.8% of the enrolled patients (n = 738,054) used vildagliptin at any time during the study with an average follow‐up time of 1.4 years, resulting in a cumulative current vildagliptin exposure of 28,330 person‐years. The adjusted IRRs (vildagliptin [± other NIADs] vs. other NIADs) were in the range of 0.61–0.97 (MI), 0.55–1.60 (ACS), 0.02–0.77 (stroke), 0.49–1.03 (CHF), and 0.22–1.02 (composite CV outcomes). The IRRs and their 95% CIs were close to 1, demonstrating no increased risk of adverse CV events, including the risk of CHF, with vildagliptin vs. other NIADs under real‐world conditions.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Tags: BRIEF REPORT Source Type: research